All diseases result from our genes and from the environment. This is conventional
teaching for first year medical students: and if the medical school is in Africa it
is hard to find a better example than blood diseases, given that in Africa, on one
hand, haemoglobinopathies affect millions of people (WHO Working Group, 1982), while
on the other hand, malaria, hookworm and nutritional deficiency (folate, or iron or
both) are the main causes of anaemia (Boele van Hensbroek et al, 2010). In medical
school we must also deal with the role of Darwinian selection in evolution. This is
a central thread throughout biology, and almost everyone agrees it applies extensively
also to the human species: yet, when it comes to giving an example, whether the class
is held in Africa or elsewhere, the teacher will fall back on how the haemoglobin
S gene has been selected in tropical areas through the relative resistance it confers
to heterozygotes against Plasmodium falciparum (see Fig 1 and Luzzatto, 1979).
Fig. 1
Plasmodium falciparum infection in a girl heterozygous for Glucose-6-phosphate dehydrogenase
(G6PD) deficiency. The blood film was stained by a procedure that causes lysis of
G6PD-deficient red cells, producing their ghost-like appearance. As G6PD deficiency
heterozygosity is a somatic cell mosaic as a result of X chromosome inactivation it
was possible to show by this procedure that P. falciparum parasitized red cells are
predominantly G6PD normal (see Luzzatto et al, 1969).
This paper is not a review, but a commentary; given that Africa is a vast and variegated
continent, we have concentrated on its tropical area – or, as from a phrase customary
during the last century, Africa ‘south of the Sahara and north of the Zambesi’. So
what are the issues faced by the practicing haematologist in Africa today? The short
answer is, exactly the same as those faced by a haematologist in any other part of
the world: only a little more complicated, for two reasons. (i) Tropical diseases
are not in lieu, but in addition to those that prevail in temperate climates. It has
long been the practice anywhere within the rain forest belt that, when a newly admitted
patient has a high fever the question is not whether he needs treatment for malaria,
but whether the fever is due ‘just’ to malaria (Esan, 1975) or to other additional
factors. Example of co-morbidity we remember include a patient who had HbSC disease
and chronic myeloid leukaemia (see also (Rosner & Grünwald, 1989); patients who had
both tuberculosis and lymphoma (see Omoti et al, 2009); a patient with sickle cell
anaemia who was at risk of dying from malaria (see McAuley et al, 2010); a young woman
with anaemia in pregnancy who was found to have paroxysmal haemoglobinuria and developed
fulminating amoebiasis (Oni et al, 1970). In the Northern part of the world co-morbidity
is quoted often as a troublesome component common in oncological practice in the elderly;
in Africa co-morbidity can be the rule rather than the exception at any age. (ii)
Many patients need haematological attention for problems that may have a precise aetiology,
but that have in fact developed essentially as a result of socio-economic reasons,
as has also happened abundantly elsewhere. For instance, hookworm anaemia is a specific
diagnosis: but when Italian workers digging the Gotthard tunnel in the late 19th century
became paler and paler until they died it was called miners’ anaemia or tunnel disease.
Once Camillo Bozzolo, Edoardo Perroncito, and Luigi Pagliani correctly surmised that
the spread of the disease had something to do with the workers wearing worn-out shoes
and being forced to defecate inside the 15 km tunnel, the problem was quickly solved
(Parona, 1894). Today in Africa the same condition, hookworm anaemia, could be called
the barefoot farmer’s anaemia: should it be treated by the administration of mebendazole
and iron or would it be better for farmers to have proper footwear? Today in Africa
the spectrum of blood diseases is largely similar to that of the rest of the world,
but disease presentation may be considerably modified by socio-economic and cultural
factors (see Figs 2 and 3). In practice, this often means late presentation with advanced
disease, and in some cases even mutilation, particularly with neoplastic disease.
The same factors also influence the rate of patients who discharge themselves or their
children against medical advice, and the degree of compliance of patients with treatment
protocols and follow up (Diagne et al, 2003): in these respects the role of social
workers is paramount and their services ought to be much enhanced.
Fig. 2
Chronic complications of sickle cell anaemia. (A) Typical ulcer of 5 years duration
on the lateral aspect of the right ankle in a 19-year-old male. Upon regular conventional
conservative care the ulcer appeared to have healed on two occasions, but unfortunately
it broke down again after minor trauma. A skin autograft was then carried out but
failed. (B) Atypical ulcer of 3 years duration in the anterior aspect of the right
thigh of a 26-year-old woman. The ulcer developed following repeated intramuscular
injections of pentazocine, administered as a pain-killer by a nurse and by the patient
herself. When self-care of the wound by dressing became unmanageable the patient saw
a specialist and subsequently travelled to India twice for skin grafting, but the
procedure failed on both occasions. It is seen that the ulcer in panel B is much deeper
than that shown in panel A, reflecting a different pathogenesis. Whereas the ulcer
in panel A was a direct complication of sickle cell anaemia, the ulcer in panel B
can be regarded as an indirect self-inflicted consequence: painful attacks prompted
administration of analgesics, and the patient, who was at the time a University student,
opted for self-medication in order to avoid frequent visits to the hospital, thus
saving time and money. The patient is still suffering from the consequences of ill-advised
inappropriate management, but this ultimately still goes back to her underlying sickle
cell anaemia. A significant impact of socio-economic status on the clinical course
of sickle cell anaemia has been documented in Nigeria (Okanyi & Akinyanju, 1993).
Fig. 3
Splenomegaly in Africa: different causes and different treatments. This 9-year-old
girl had a massive spleen. A traditional doctor had applied tattoos or scarifications
that did not control the condition. A likely diagnosis is hyper-reactive malarial
splenomegaly (Bedu-Addo & Bates, 2002), and it is hoped that the condition will respond
to prolonged administration of antimalarial drugs (Sagoe, 1970).
Co-morbidity problems and other complex clinical situations can be solved by clinical
acumen sharpened by experience, diligent review of the literature, appropriate interactions
with colleagues, and obstinate perseverance. On the other hand, dealing with major
public health problems that manifest through a high prevalence of various types of
anaemia (see Table I) is a tall order: what then, in this respect, is the role of
a haematologist? It would be certainly wrong to say that a haematologist should not
be concerned with the matter; but it would be equally wrong to blame haematologists
for the death of children with malaria and severe anaemia or of women with acute blood
loss from placenta praevia who have not been transfused promptly enough. We do have
an obligation to pinpoint these problems, but this has been done in the literature
of the past several decades: it will not help if we continue to designate problems
as medical when they are, in fact, economic. We must recognize that such problems
ought to be resolved by adopting appropriate public health policies, in particular
by improvement of the infrastructure; and that ultimately the basis for such decisions
is the will or at least the willingness to make political choices.
Table I
Common anaemias at the border between haematology and public health
Designation
Aetiopathogenesis (main factor)
‘Real’ cause
Standard therapy
Long-term management
Hookworm anaemia
Chronic blood loss from infestation with Anchilostoma duodenale
Poor hygiene/poverty
Mebendazole, oral iron
Preventing worm infestation
Malarial anaemia
Recurrent infection with Plasmodium falciparum and other Plasmodia
High rate transmission of malaria by Anophelines
Anti-malarial chemotherapy
Eradication of malaria transmission
Severe anaemia in pregnancy
Increased folate requirement
Poor folate intake
Folic acid, folinic acid
Improving nutrition
Severe post-partum anaemia
Ante-partum or post-partum haemorrhage
Inadequate ante-natal or obstetric care
Blood transfusion
Improving ante-natal care
Nowadays, much of what a haematologist is called upon to do has the onco- prefix,
and Africa is no exception. It is pertinent to recall that our understanding of lymphoma
owes much to an African disease which, following the painstaking epidemiological studies
conducted half a century ago by Dennis Burkitt (Burkitt, 1962), carries his name.
It was on biopsy tissue from East Africa and from cell lines grown in Ibadan (Osunkoya
& Mottram, 1967) that the t(8;14) translocation was discovered in Burkitt lymphoma.
The subsequent identification of IGH (previously IgH) and MYC (previously c-myc) as
partner genes that become juxtaposed and dysregulated as a result of this translocation
spelled a new paradigm in the mechanism of oncogenesis (Klein, 1983). Today, accurate
diagnosis of most types of lymphoma and of acute leukaemia can be done in most haematology
departments in Africa; however, with a few exceptions, this is followed all too often
by the frustrating feeling that one cannot provide optimal treatment: sometimes because
of limited access to the necessary drugs, sometimes because of inadequate facilities
(e.g. for bone marrow transplantation), sometimes both. However, complaining about
shortages will not get us anywhere; rather, it would be probably ideal if each department
worked out, for internal consumption, a list in three sections (see Table II): (A)
Conditions we can deal with adequately. (B) Conditions for which we offer treatment
that may not be optimal in 2011, but is nevertheless of proven efficacy. In this respect,
treatment approaches using less intense and less costly multi-agent chemotherapy are
sometimes successfully introduced with encouraging results (Fasola et al, 2002; Hesseling
et al, 2008) (C) Conditions for which we cannot offer adequate treatment; these cases,
i.e., those who can afford it and especially potentially curable patients, must be
recommended to attend elsewhere for treatment. Clearly the contents of the three sections
will vary from place to place: but it would be an advantage for both doctors and patients
to have taken the deliberate step of setting and stating in advance a policy to which
one can refer, even though it is hoped that adjustments will be needed frequently.
Table II
Management of relatively common conditions in onco-haematology: a few examples
Category
Condition
Basic requirements for treatment
Comments
A
Chronic lymphocytic leukaemia
Fludarabine, rituximab, chlorambucil
Typing for risk stratification may be out-sourced
Polycythaemia rubra vera
Phlebotomies; hydroxycarbamide
Burkitt lymphoma
Cyclophosphamide, vincristine, doxorubicine, prednisone
B
Hodgkin lymphoma
ABVD, BEACOPP; radiotherapy
Salvage therapy may not be available
Myeloma
Melphalan, prednisone, auto-BMT
Second and third line drugs may not be available
Common acute lymphoblastic leukaemia
Vincristine, prednisone, intrathecal MTX
C
Chronic myeloid leukaemia
Imatinib; allogeneic BMT
Imatinib is expensive; allogeneic BMT may not be available
Acute leukaemia in adults
Several drugs, allogeneic BMT
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide,
adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone; MTX, methotrexate;
BMT, bone marrow transplantation.
It must be acknowledged that, in many countries, haematology has become sub-specialized
to the point of fragmentation, with a haematologist who mainly performs transplants
being hardly likely to ever see a patient with haemophilia, and with the myeloma expert
having nothing to do with blood transfusion. In Africa the general haematologist species
is not yet extinct, and contributions in all of these areas have come from general
haematologists (e.g. see Essien et al, 1970; Worlledge et al, 1974; Kasili, 1976;
Williams, 1985): this means greater demands on one’s time in order to keep up to date,
but also a command of a wider field, with a combination of clinical and laboratory
skills that can be turned to one’s advantage. Many haematologists in many parts of
the world have also given up looking down the microscope, but not so in Africa where
more limited resources must be exploited fully: and fortunately a good microscope
does not obsolesce as quickly as a flow cytometry machine. So let us not underestimate
how many blood conditions can be diagnosed or at least suspected just by looking carefully
at a blood film; it is possible that, in the future, selected African haematologists
will be needed to teach blood morphology in other continents!
Against this background, if in a brief commentary we are to single out one disease
as the Leitmotiv of African haematology, it must be undoubtedly the haemoglobinopathies,
and specifically sickle cell disease. Last year was the centennial anniversary of
the description of sickle cells by Herrick (1910). During these one hundred years
there have been tremendous advances in understanding the disease, but for the first
three quarters of that century there has been remarkably little progress in improving
its management. Then, three developments occurred: (i) prenatal diagnosis (Old et
al, 2000), (ii) bone marrow transplantation (Vermylen et al, 1994; Walters et al,
1996) and (iii) hydroxycarbamide (HC, previously termed hydroxyurea) (Charache, et
al 1995; Zimmerman et al, 2004). For each one of these developments there are pros
and cons, including difficult clinical decisions and weighty ethical issues, which
are not expanded upon in this article. But, we must ask a simple question: to what
extent have these advances been of benefit to patients in Africa, where the large
majority (estimated 8 million) of patients with sickle cell disease live? The facilities
required for bone marrow transplantation are considerable, but they are certainly
present in South Africa (Wood et al, 2009); the facilities required for prenatal diagnosis
are relatively modest, especially since this has shifted from haemoglobin-based to
DNA-based (Adewole et al, 1999). As for HC, the daily cost of this drug per patient
in the UK is about 20 p: unfortunately this cost is higher in Africa, where it is
estimated that, in many countries, no more than 1% of patients with sickle cell disease
receive HC; and this to us is a shame. Yet, significant background information is
available: a search in PubMed for sickle cell disease AND Africa yields no less than
1386 hits, about one-tenth of the total sickle cell disease hits (including, for instance,
Konotey-Ahulu, 1974; Bienzle et al, 1975; Akinyanju et al, 2005; Labie & Elion, 2010;
Makani et al, 2011). It is true that, although HC is a reversible inhibitor of deoxyribonucleoside
diphosphate reductase and not an alkylating agent, questions are still being asked
about the possible risk of cancer from this drug: however, there is no theoretical
or empirical reason why HC should be less beneficial or less safe for African patients
compared to other patients elsewhere (Jones et al, 2010; Svarch et al, 2006; Steinberg
et al, 2010).
What is the way forward? Given that little research support is available, should we
concentrate more on laboratory experiments, clinical data collection, outcome research
or educating the public? As stated at the beginning of this article, we must strike
a balance between tackling problems in which haematologists can make a difference
and taking on others that are much larger than all haematology departments in the
world pooled together. To treat an individual with folate deficiency or with hookworm
anaemia is easy and gratifying; but unless poverty is relieved it will be a drop in
the ocean, and to relieve poverty we must – regardless of being haematologists – mitigate
as citizens or go into politics. When poverty is relieved these diseases will disappear,
just like protein-calorie malnutrition in children. The practice of haematology in
an African country, like in any other country, is part and parcel of a national structure
that depends on a political system: inevitably this has a strong impact on the delivery
of optimal haemato-oncology treatments to patients. In Africa, this challenge is initially
tied up with the availability of, and access to, the necessary drugs; and it is compounded
by the emergence of human immunodeficiency virus (HIV) as a major threat to blood
safety (Lefrère et al, 2011).
In the meantime, we have an obligation to fulfill our specific professional commitments.
There is no doubt that international initiatives could help, as indicated by a recent
report (Odame, 2010); at the same time, international partnerships could also provide
the impetus for research and help to target resources towards the goal of improving
patient care. Let us start with a campaign to provide every African who has sickle
cell disease with folic acid, antimalarial prophylaxis and, whenever indicated, HC.